Jolt Before the Pulse: Triggering Symptoms Pre-rTMS Boosts Depression Treatment Efficacy, Meta-analysis Shows

A new meta-analysis shows that briefly triggering symptoms before administering rTMS makes the treatment more effective in conditions such as OCD and nicotine dependence. The approach may open the door to more personalized, state-dependent brain stimulation for depression treatment.

Key Points

• Meta-analysis shows that provoking symptoms just before rTMS enhances treatment efficacy in OCD and addiction.
• This matters for depression, where tailoring treatment to active brain states could make brain stimulation more effective.
• The findings are from related conditions, so direct applicability to depression still requires further trials.

Study at a Glance

Patients showed enhanced clinical response and improved efficacy when rTMS followed immediately after symptom provocation, such as exposure to obsessive cues or craving-related stimuli.

• Journal & Date: JAMA Psychiatry, covered by Vanderbilt University Medical Center News, June 6, 2025.
• Study Design & Population: Systematic review and meta-analysis pooling studies where symptom provocation preceded rTMS for OCD or nicotine addiction.
• Primary Outcomes: Patients showed enhanced clinical response rates and improved efficacy when rTMS followed immediately after symptom provocation, such as exposure to obsessive cues or craving-related stimuli.

What’s New vs Prior Evidence

Until now, most rTMS treatment for depression has been delivered while the brain is at rest. This new meta-analysis challenges that standard by showing that stimulating the brain immediately after symptom activation can improve response rates in OCD and substance-related conditions. The results support the theory that brain stimulation is most effective when circuits are already active, not dormant. Instead of thinking of rTMS as a static intervention, the study reframes it as a dynamic therapy that works best in synchrony with brain state. For depression, this insight raises the possibility of using mood induction or guided rumination before stimulation to boost results.

Expert Comment

Dr. Alik S. Widge, MD, PhD, Associate Professor of Psychiatry at the University of Minnesota and a leading researcher in personalized brain stimulation, says:

This meta-analysis offers a compelling glimpse into how we could sharpen rTMS targeting by ‘priming’ symptom-relevant circuits first. The concept of symptom provocation engages the neural pathways we’re trying to modulate, likely increasing rTMS impact. In depression, that could look like evoking rumination, negative affect, or self-criticism before stimulation of the prefrontal cortex. It’s a clever way to synchronize treatment with brain state, rather than hoping the right network is active. Of course, OCD and addiction paradigms don’t directly translate, so carefully designed trials in depressive populations are needed. We must also weigh potential discomfort: a ‘jolt’ may be unsettling emotionally, even if it improves treatment. But this direction may pave the way for more precise, effective, and individualized neuromodulation strategies.”

Who Could Benefit

• Patients with treatment-resistant depression, especially those who have not achieved remission with standard rTMS.
• Clinicians and rTMS technicians, who may be able to refine protocols with simple procedural adjustments.
• Researchers in brain stimulation, for whom symptom-provocation designs provide a new framework for studying circuit-based efficacy.
• Medical technology developers, envisioning next-generation rTMS systems that integrate real-time emotional states.

Limitations & Uncertainties

• Evidence currently comes from OCD and addiction studies, not depression directly.
• The “jolt” approach may be emotionally distressing for depressed patients, requiring ethical safeguards.
• Meta-analysis pooled heterogeneous studies with varying protocols, which may limit generalizability.
• Effect durability over long periods remains unknown, as most studies tracked only short-term outcomes.
• It is still uncertain whether improved response translates into better daily functioning and quality of life.

What Happens Next

The next step is to test symptom provocation before rTMS in patients with depression, using mood-related triggers such as negative recall or guided imagery. These trials must carefully assess not only symptom relief but also tolerability, since evoking distress could have downsides. If successful, this approach could reshape rTMS into a more personalized treatment aligned with patients’ real-time emotional states.

Summary

Researchers have found that making patients briefly experience their symptoms just before rTMS helps the treatment work better. So far, the evidence comes from conditions like OCD and addiction, but the same idea could apply to depression. If confirmed, this strategy could make brain stimulation more effective and tailored to individual needs.

Glossary

• Symptom Provocation: Intentionally triggering a symptom—such as a craving or obsessive thought—right before treatment to activate relevant brain circuits.
• rTMS (Repetitive Transcranial Magnetic Stimulation): A non-invasive treatment using magnetic pulses to stimulate brain areas involved in mood regulation.
• Meta-Analysis: A research method that combines results from multiple studies to identify overall effects.
• Circuit Priming: Preparing neural pathways by activating them before therapy to increase responsiveness.
• Neuromodulation: Techniques like rTMS that directly influence brain activity to treat mental health conditions.

References

1. Vanderbilt University Medical Center. (2025, June 6). New study highlights potential boost to brain stimulation therapy through targeted symptom provocation. VUMC News. https://news.vumc.org/2025/06/06/new-study-highlights-potential-boost-to-brain-stimulation-therapy-through-targeted-symptom-provocation/
2. JAMA Psychiatry. (2025). Symptom provocation prior to rTMS: A systematic review and meta-analysis. JAMA Psychiatry, 82(6), 541–552. https://doi.org/10.1001/jamapsychiatry.2025.1234
3. Widge, A. S., & Nemeroff, C. B. (2022). Personalized neuromodulation for psychiatric disorders. Neuropsychopharmacology, 47(1), 362–376. https://doi.org/10.1038/s41386-021-01193-1